Hormonal contraception and risk of venous thromboembolism: national follow-up study

Objective To assess the risk of venous thrombosis in current users of different types of hormonal contraception, focusing on regimen, oestrogen dose, type of progestogen, and route of administration. Design National cohort study. Setting Denmark, 1995-2005. Participants Danish women aged 15-49 with no history of cardiovascular or malignant disease. Main outcome measures Adjusted rate ratios for all first time deep venous thrombosis, portal thrombosis, thrombosis of caval vein, thrombosis of renal vein, unspecified deep vein thrombosis, and pulmonary embolism during the study period. Results 10.4 million woman years were recorded, 3.3 million woman years in receipt of oral contraceptives. In total, 4213 venous thrombotic events were observed, 2045 in current users of oral contraceptives. The overall absolute risk of venous thrombosis per 10 000 woman years in non-users of oral contraceptives was 3.01 and in current users was 6.29. Compared with non-users of combined oral contraceptives the rate ratio of venous thrombembolism in current users decreased with duration of use (<1 year 4.17, 95% confidence interval 3.73 to 4.66, 1-4 years 2.98, 2.73 to 3.26, and >4 years 2.76, 2.53 to 3.02; P<0.001) and with decreasing dose of oestrogen. Compared with oral contraceptives containing levonorgestrel and with the same dose of oestrogen and length of use, the rate ratio for oral contraceptives with norethisterone was 0.98 (0.71 to 1.37), with norgestimate 1.19 (0.96 to 1.47), with desogestrel 1.82 (1.49 to 2.22), with gestodene 1.86 (1.59 to 2.18), with drospirenone 1.64 (1.27 to 2.10), and with cyproterone 1.88 (1.47 to 2.42). Compared with non-users of oral contraceptives, the rate ratio for venous thromboembolism in users of progestogen only oral contraceptives with levonorgestrel or norethisterone was 0.59 (0.33 to 1.03) or with 75 μg desogestrel was 1.12 (0.36 to 3.49), and for hormone releasing intrauterine devices was 0.90 (0.64 to 1.26). Conclusion The risk of venous thrombosis in current users of combined oral contraceptives decreases with duration of use and decreasing oestrogen dose. For the same dose of oestrogen and the same length of use, oral contraceptives with desogestrel, gestodene, or drospirenone were associated with a significantly higher risk of venous thrombosis than oral contraceptives with levonorgestrel. Progestogen only pills and hormone releasing intrauterine devices were not associated with any increased risk of venous thrombosis.

[1]  Ø. Lidegaard.  The influence of thrombotic risk factors when oral contraceptives are prescribed a control‐only study , 1997 .

[2]  S. Shakir,et al.  Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. , 2005, British journal of clinical pharmacology.

[3]  L. Heinemann,et al.  The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. , 2007, Contraception.

[4]  H. Jick,et al.  Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives , 2001, The Lancet.

[5]  J. Vandenbroucke,et al.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen , 1995, The Lancet.

[6]  M. Gordon.  Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiolJick SS, Kaye JA, Russmann S, et al (Bosten Univ, Lexington, Mass) Contraception 73:223–228, 2006§ , 2007 .

[7]  G. Leydon,et al.  Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database. , 1999, Human reproduction.

[8]  W. Spitzer,et al.  The differential risk of oral contraceptives: the impact of full exposure history. , 1999, Human reproduction.

[9]  S Kreiner,et al.  Oral contraceptives and venous thromboembolism. A case-control study. , 1998, Contraception.

[10]  Gynecologica Scandinavica.  The influence of thrombotic risk factors when oral contraceptives are prescribed , 1997 .

[11]  H. Jick,et al.  Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis , 2000, BMJ : British Medical Journal.

[12]  C. Paul,et al.  Oral contraceptives and fatal pulmonary embolism , 2000, The Lancet.

[13]  T. Farley,et al.  Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease , 1995 .

[14]  J. Vandenbroucke,et al.  Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. , 1999, Archives of internal medicine.

[15]  W. Spitzer,et al.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study , 1996, BMJ.

[16]  S. Marsoni,et al.  Fluorouracil and folinic acid in colon cancer , 1995, The Lancet.

[17]  H. Jick,et al.  Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components , 1995, The Lancet.

[18]  H. Jick,et al.  Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. , 2006, Contraception.

[19]  T. Farley,et al.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. , 1995, Lancet.

[20]  World Health Organization Collaborative Study of Cardiov Contraception.  Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease , 1995, The Lancet.

[21]  S. Kreiner,et al.  Oral contraceptives and venous thromboembolism: a five-year national case-control study. , 2002, Contraception.

[22]  A. Walker,et al.  Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives , 2007, Obstetrics and gynecology.

[23]  World Health Organization Collaborative Study of Cardiov Contarception.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study , 1995, The Lancet.

[24]  R. Farmer,et al.  Population-based study of risk of venous thromboembolism associated with various oral contraceptives , 1997, The Lancet.